Typically when a drug or formulation goes OTC you see rise in revenues, with the potential for a rise in employment as well, but it's too early to say.

We know there are times when the power company needs more power and times they don't. They know they'll get the water back. What we need to do is sit down and see if there's something we can work out for the both of us.

When they see that water running over the falls, they're looking at their life blood going to the ocean. It's not just a problem for farmers, it's a problem for everyone.

When you have a massively prescribed and consumed drug like Vioxx, and if something goes wrong, you have a lot of potential for (liability) exposure. Vioxx has that kind of profile. Whether or not each and every drug will have that profile, it's hard to say.

Cisco's inability to reduce its inventory after the October quarter when revenues grew 14 percent quarter over quarter and inventory grew by 59 percent quarter over quarter reaffirms our view that we have not yet seen the worst of the inventory correction for semiconductor suppliers.

When that dog jumps, the crowd just goes 'a-w-w-w!'